{"id":10010,"date":"2021-05-25T14:53:36","date_gmt":"2021-05-25T21:53:36","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10010"},"modified":"2021-05-27T14:54:14","modified_gmt":"2021-05-27T21:54:14","slug":"safety-and-immunogenicity-of-anti-sars-cov-2-messenger-rna-vaccines-in-recipients-of-solid-organ-transplants","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/25\/safety-and-immunogenicity-of-anti-sars-cov-2-messenger-rna-vaccines-in-recipients-of-solid-organ-transplants\/","title":{"rendered":"Safety and Immunogenicity of Anti\u2013SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Prevalence of anti-SARS-CoV-2 antibodies in a cohort of 367 solid organ transplant recipients in France who received an mRNA COVID-19 vaccine was 1.4% at baseline, 6.3% prior to the second dose, and 34% at 1 month after the second dose. The vaccines were well tolerated with only one serious adverse event reported.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Marion et al.\u00a0(May 25, 2021). Safety and Immunogenicity of Anti\u2013SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.7326\/M21-1341\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.7326\/M21-1341<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prevalence of anti-SARS-CoV-2 antibodies in a cohort of 367 solid organ transplant recipients in France who received an mRNA COVID-19 vaccine was 1.4% at baseline, 6.3% prior to the second dose, and 34% at 1 month after the second dose. The vaccines were well tolerated with only one serious adverse event reported. Marion et al.\u00a0(May&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/25\/safety-and-immunogenicity-of-anti-sars-cov-2-messenger-rna-vaccines-in-recipients-of-solid-organ-transplants\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-10010","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10010"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10010\/revisions"}],"predecessor-version":[{"id":10011,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10010\/revisions\/10011"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10010"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}